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A Esclerose Lateral Amiotrópica (ELA) é uma doença progressiva e fatal caracterizada 
pela degeneração selectiva dos neurónios motores do córtex motor, tronco cerebral e 
medula espinal, que provoca atrofia muscular, paralesia e morte por falha respiratória. A 
etiologia da doença continua desconhecida, mas com um consenso de que o dano dos 
neurónios motores é causado por uma rede de processos patológicos complexos. Os 
mecanismos envolvidos na degeneração dos neurónios motores são melhor conhecidos 
num subtipo da doença causada por mutações na enzima superóxido dismutase 1 (SOD1). 
Esta enzima actua na eliminação de radicais livres de oxigénio e na ELA o processo de 
degeneração neuronal deve-se a um ganho de função da SOD1. A adenosina tem uma 
função importante na modulação da transmissão sináptica no SNC e SNP, actuando a dois 
níveis: inibitório, modulado pelos receptores do subtipo A1 e excitatório, mediado pelos 
receptores do subtipo A2A. É conhecido que a expressão dos receptores A1 e A2A da 
adenosina está alterada nalgumas doenças neurodegenerativas, mas o seu papel na ELA é 
ainda muito pouco conhecido. 
O objectivo deste trabalho foi determinar o efeito da ELA na expressão proteica e de 
mRNA dos receptors A1 e A2A da adenosina no decurso da doença. O modelo de murganhos 
transgénicos para o gene SOD1 humano com a mutação G93A foi usado neste trabalho. Os 
níveis proteicos e de mRNA de ambos os receptores foram quantificados através das 
técnicas de immunoblotting e PCR quantitativo em tempo real, respectivamente. Foram 
estudados diferentes tecidos do SNC e SNP, nomeadamente, córtex e medula espinal 
(apenas immunoblotting) e nervo frénico-diafragama, de animais selvagens e portadores da 
doença nas fases pre-sintomática (4-6 semanas) e sintomática (13-14 semanas).  
Resultados deste estudo indicaram níveis proteicos não alterados nos SNC e SNP do 
receptor A1 ao longo da progressão da doença. No entanto, observou-se uma 
sobreexpressão dos receptores A2A no córtex na fase pre-sintomática e um decréscimo na 
fase sintomática. Os outros tecidos mantiveram-se inalterados no que se refere aos 
receptores A2A em ambas as fases da doença. A avaliação da expressão de mRNA no 
diafragma não revelou quaisquer alterações em ambos os receptores da adenosina durante 
a progressão da doença. Assim, no que se refere aos receptores da adenosina em ELA, as 
primeiras alterações parecem ocorrer logo no início da doença nos receptores A2A do SNC. 
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Amyothrophic Lateral Sclerosis (ALS) is a progressive and fatal disease categorized by 
a selective degeneration of motor neurons from the cerebral cortex, brainstem and spinal 
cord that provokes muscle atrophy, progressive paralysis and death due to respiratory 
failure. The etiology of most ALS cases remains unknown but there is a current consensus 
that motor neuron degeneration is caused by a complex interaction between multiple 
pathogenic processes. The mechanisms of motor neuron degeneration are best understood 
in the subtype of disease caused by mutations in the enzyme superoxide dismutase 1. This 
enzyme is enrolled in the degradation of free oxygen radicals and in ALS neuronal damage is 
due to its gain-of-function. Adenosine has a central role as a neuromodulator of the CNS and 
PNS synaptic transmission. Adenosine acts at two levels: inhibitory through the subtype A1 
receptor and excitatory through the subtype A2A receptor. Variation on the expression of A1 
and A2A receptors has been identified in some neurodegenerative diseases, but their role in 
ALS is not yet understood.  
The objective of this work was to determine the effect of ALS on the protein and mRNA 
expression of A1 and A2A adenosine receptors through disease progression. The transgenic 
model of mice carrying the human SOD1 gene with the G93A mutation was used in this work. 
Protein and mRNA levels of both receptors were quantified through immunblotting and 
quantitative real time PCR, respectively. Different tissues of the CNS and PNS, namely 
cortex and spinal cord (immunoblotting only) and phrenic nerve-diaphragm were studied in 
wild-type and transgenic mice in the pre-symptomatic (4-6 weeks) and symptomatic (13-14 
weeks) phases of the disease. 
Results from this study indicate unaltered A1 receptor protein levels at the CNS and 
PNS through disease progression. However, there is an overexpression of A2A receptors in 
the cortex of pre-symptomatic mice and a decrease in the symptomatic phase. The A2A 
receptors are unaltered in the other tissues in both phases of the disease. The mRNA 
evaluation does not reveal significant alterations in both adenosine receptors during disease 
progression. Thus, regarding adenosine receptors in ALS, the first changes seem to occur 
early in the disease at the CNS in A2A receptors. 
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A1R – A1 adenosine receptor 
A2AR – A2A adenosine receptor 
A2BR – A2B adenosine receptor 
A3R – A3 adenosine receptors 
ADP – Adenosine Diphosphate 
ALS – Amyothrophic Lateral Sclerosis 
ATP – Adenosine Triphosphate 
BSA – Bovine Serum Albumin 
CNS – Central Nervous System 
CTRL – Control (referring to Wild-type 
endogenous SOD1 mouse model) 
DEPC – Diethylpyrocarbonate 
dNTP - Deoxynucleotide Triphosphates 
DTT – Dithiothreitol 
ECL - Enhanced Chemiluminescence 
EDTA - Ethylenediaminetetracetic Acid 
ER – Endoplasmic Reticulum 
FTD – Frontotemporal Dementia 
HEPES - 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
LMN – Lower Motor Neuron 
MND – Motor Neuron Diseases 
NADH - Nicotinamide Adenine Dinucleotide 
Hidrogenase 
NMJ – Neuromuscular Junction 
NP-40 – Nonyl Phenoxypolyethoxylethanol 
PBS - Phosphate Buffered Saline 
PD – Parkinson’s Disease 
PMSF – Phenylmethanesulfonyl Fluoride 
PNS – Peripheral Nervous System 
PST – Pre-Symptomatic phase mice 
PVDF – Polyvinylidene Difluoride 
RIPA - Radio-Immunoprecipitation Assay 
ROS – Reactive Oxygen Species 
RPM - Revolutions Per Minute 
SDS - Sodium Dodecyl Sulfate 
SOD1 – Superoxide Dismutase 1 (referring 
to transgenic mouse model for human 
SOD1 with G93A mutation) 
ST – Symptomatic phase mice 
TBS – Tris Buffered Saline 
TBS-T - Tris-Buffered Saline with Tween 
TDB – Tail Digestion Buffer 















1. Amyotrophic Lateral Sclerosis 
1.1. Historical background 
It was in the latter half of the 19th century that the initial steps towards the unraveling of 
one of the most common motor neuron diseases (MND) were accomplished. Using clinical 
cases and autopsy material, a technique known as “anatomo-clinical method”, the famous 
French neurobiologist and physician Jean-Martin Charcot (Figure 1), showed that it could be 
possible to correlate anatomical lesions in the nervous system by the presence of clinical 
signs (Goetz et al., 1995; Goetz, 2000 and Rowland, 2001). In this context, his first major 
contribution was in 1865 (Charcot, 1865) when he presented a case of a young woman who 
developed profound weakness and showed increased muscle tone, with contractures of all 
extremities, despite she had no intellect or sensory abnormalities, and her urinary control 
was normal. At the autopsy study, Charcot found specific and isolated lateral column 
degeneration in the spinal cord: 
 
“On careful examination of the surface of the spinal cord, on both 
sides in the lateral areas, there are two brownish-gray streak marks 
produced by sclerotic changes. These grayish bands begin outside 
the line of insertion of the posterior roots, and their anterior border 
approaches, but do not include, the entrance area of the anterior 
roots. They are visible throughout the thoracic region and continue, 
though greatly thinning out, up to the widening point of the cervical 
cord. Below, they are barely visible in the thoracolumbar region. 
Transverse sections taken at different levels allow one to see that 
the lateral columns have in their most superficial and posterior 
regions, a gray, semitransparent appearance, rather gelatinous.... 
At no point does the diseased tissue penetrate the gray matter 
which remains unaffected.” (Charcot, 1865). 
 
In a second apparently unrelated observation (Charcot & Joffroy, 1869) with his 
colleague, Joffroy, they found pediatric cases of infantile paralysis in which the spinal cord 
lesions were systematically limited to the anterior horns of the grey matter. Thus raised the 
hypothesis that the spinal cord motor system was organized into two parts, and that lesions 
Figure 1 | Jean-Martin Charcot (1825-1893). Jean-Martin Charcot was a French neurobiologist and physician       
that first characterized Amyotrophic Lateral Sclerosis. 
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affecting each part cause different clinical signs. These conclusions became the pillars of 
modern neurology: when gray matter motor nuclei are damaged, weakness is associated 
with muscular atrophy in the body areas supplied by those cells, whereas when white lateral 
column damage occurs, weakness is associated with progressive contractures and 
spasticity. Charcot’s achievement to make sense of these evidences, led him for the first time 
in 1874 (Charcot, 1874) to use the term Amyotrophic Lateral Sclerosis to refer to this 
disorder and stated that: 
 
“I do not think that elsewhere in medicine, in pulmonary or cardiac pathology, greater precision can be 
achieved. The diagnosis as well as the anatomy and physiology of the condition “amyotrophic lateral 
sclerosis” is one of the most completely understood conditions in the realm of clinical neurology.” 
(Charcot, 1887). 
 
ALS first became known as Charcot’s sclerosis but in North America the term “ALS” is 
used interchangeably with “Lou Gehrig’s disease” in memory of the famous baseball player 
who died of the disease in 1941. The word Amyotrophic comes from the Greek language. "A" 
means no, "Myo" refers to muscle, and "Trophic" means nourishment – "No muscle 
nourishment". When a muscle has no nourishment, it atrophies or wastes away. "Lateral" 
identifies the areas in a person's spinal cord where portions of the nerve cells that signal and 
control the muscles are located. As this area degenerates it leads to scarring or hardening 
("sclerosis") in the region (The ALS Association, 2010). 
 
1.2. Epidemiological and Clinical features of ALS 
After 140 years, ALS is the most common adult-onset motor neuron disease. With a 
uniform worldwide incidence (frequency of new cases per year) of approximately 1-2 per  
100 000 individuals and a prevalence (the proportion of affected individuals in the population) 
of 4-6 per 100 000. It affects people of all races and ethnic backgrounds and more commonly 
men than women (the male:female ratio is 3:2) (Kiernan et al., 2011). There are a few 
exceptions with higher frequency of cases, such as Guam (Reed et al., 1975), the Kii 
Peninsula of Japan (Kimura, 1965) and the southern lowlands of western New Guinea 
(Gajdusek & Salazar, 1982). Although 90-95% of cases have been classed as sporadic ALS 
(SALS) with no apparent genetic link, in the remaining 5-10% of instances the disease is 
inherited in an autosomal dominant manner, referred as familial ALS (FALS). The mean age 
of onset is 45-60 years in both forms of ALS. The primary hallmark is the degeneration of the 
upper motor neurons (UMN) of the motor cortex and of the lower motor neurons (LMN), 
which extend through the brainstem and spinal cord to innervate skeletal muscles. Clinical 
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presentation (figure 2) varies but most commonly consists of progressive muscle weakness, 
fasciculations (twitching muscles), atrophy and spasticity (the persistent contraction of certain 
muscles, which causes stiffness and interferes with gait, movement or speech). However 
ALS clearly spares cognitive ability, sensation, and autonomic nervous functions, like eye 
movement and control of urinary sphincters. It is less well recognized that at least 30% of 
small interneurons in the motor cortex and spinal cord also degenerate (Cleveland & 
Rothstein, 2001). Generally fatal within 1-5 years of onset, ALS culminates in death from 
respiratory failure because of denervation of respiratory muscles and diaphragm. The causes 
of almost all occurrences of the disease remain unknown (Pasinelli & Brown, 2006; Andersen 
& Al-Chalabi, 2011). 
Regrettably there is no primary theraphy for this disorder and the single drug 
approved for use in ALS, Rilutek® (riluzole), acting through inhibition of pre-synaptic 
glutamate release, only slightly prolongs survival for a few months (Bensimon et al., 1994). 
Symptomatic measures (for example, feeding tube and respiratory support) are the mainstay 




1.3. Superoxide dismutase 1 mutation 
The identification of some of the genetic subtypes of ALS (table 1) has established key 
molecular and pathogenic mechanisms, which are applicable not only to the minority of 
cases that carry FALS mutations, but also to SALS more broadly. However, the discovery of 
Cu/Zn superoxide dismutase’s (SOD1) role in FALS (Rosen et al., 1993) offered the first 
insight to unravel ALS. The authors reported that mutations in this enzyme occur in an 
autosomal dominant manner in adult-onset ALS (ALS1) and account for 2-3% of ALS cases 
and about 15%-20% of instances of FALS. 
 
Figure 2 | Clinical features of muscle wasting in 
patients with ALS. (A) Proximal and symmetrical 
upper limb wasting results in an inability to lift arms 
against gravity. (B) Recessions above and below the 
scapular spine, indicating wasting of supraspinatus 
and infraspinatus muscles, as well as substantial 
loss of deltoid muscle. (C) Disproportionate wasting 
of the thenar muscles combined with the first dorsal 
interossei. (D) Substantial wasting of the tongue 
muscles. Note the absence of palatal elevation 
present on vocalisation. Difficulty in mouth opening 
and swallowing (extracted from Kiernan et al., 2011). 
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Table 1 | Reviewed genes associated with familial ALS. (adapted from Ferraiuolo et al., 2011). 
 
SOD1 dismutates free oxygen radicals into O2 and hydrogen peroxide (H2O2). H2O2 is 
then converted to H2O by either catalase or glutathione peroxidase (Nicholls & Ferguson, 
2002). The SOD1 gene comprises five exons that encode 153 evolutionarily conserved 
amino acids which, together with a catalytic copper ion and a stabilizing zinc ion, form a 
subunit. Through covalent binding, pairs of these subunits form the SOD1 homodimers 
(Cleveland & Rothstein, 2001). 
Following linkage analysis, in 1993, using modern genetic mapping methods and with 
DNAs from patients suffering from familial ALS, Rosen and colleagues (1993) identified 11 
missense mutations in the SOD1 gene in 13 of 18 pedigrees with high-penetrance 
dominantly inherited FALS. Since then, 166 SOD1 mutations have been reported (figure 3) to 
be associated with ALS, plus 8 silent mutations and 9 intronic variants, presumed to be 
nonpathogenic. Of the 166 disease associated mutations, 147 are of the missense type. The 
remaining 19 mutations are nonsense and deletion mutations that result in a change in 
Genetic ALS subtype Chromosomal locus Gene (gene symbol) 
Oxidative stress 
ALS1 21q22 Superoxide dismutase 1 (SOD1) 
RNA processing 
ALS4 9q34 Senataxin (SETX) 
ALS6 16p11.2 Fused in sarcoma (FUS) 
ALS9 14q11.2 Angiogenin (ANG) 
ALS10 1p36.2 TAR DNA-binding protein (TARDBP) 
Endossomal trafficking and cell signalling 
ALS2 2q33 Alsin (ALS2) 
ALS11 6q21 Polyphosphoinositide phosphatase (FIG4) 
ALS8 20q13.3 Vesicle-associated protein-associated protein B (VAPB) 
ALS12 10p13 Optineurin (OPTN) 
Glutamate excitotoxicity 
ND 12q24 D-amino acid oxidase (DAO) 
Ubiquitin/protein degradation 
ND 9p13-p12 Valosin-containing protein (VCP) 
ALSX Xp11 Ubiquilin 2 (UBQLN2) 
Cytoskeleton 
ALS-dementia-PD 17q21 Microtubule-associated protein tau (MAPT) 
Other genes 
ALS5 15q15-q21 Spatacsin (SPG11) 
ALS-FTD 9p13.3 σ Non-opioid receptor 1 (SIGMAR1) 
ALS-FTD 9q21-q22 Chromosome 9 open reading frame (C9ORF72) 
Unknown genes 
ALS3 18q21 Unknown 




length of the SOD1 polypeptide (Cleveland & Rothstein, 2001; Turner & Talbot, 2008). The 
pathological effects of SOD1 mutations are not thought to result from loss of dismutase 
activity but rather from gain-of-function effects through which the protein acquires one or 
more toxic properties. This theory is supported by several lines of evidence, including the 
absence of motor neuron degeneration in hSOD1-null mice and its occurrence in transgenic 
mice overexpressing mutant forms of SOD1, irrespective of residual dismutase activity 
(Gurney et al., 1994). 
 
 
1.4. SOD1 mouse models 
1.4.1. SOD1 overexpressing and knockout models 
Mice deficient for SOD1 were generated by targeted gene deletion. Homozygote SOD1 
knockout mice were viable and appeared to develop without any obvious motor abnormalities 
(Ho et al., 1998; Reaume et al., 1996). Hence, disruption of SOD1 alone appeared to be 
insufficient to cause spontaneous motor neuron degeneration in mice without injury or 
challenge. SOD1 knockouts are repeatedly reported to be normal or healthy which is 
interpreted as a major defeat for a loss-of-activity hypothesis for SOD1 mutations. However, 
SOD1 null mice develop chronic age-related peripheral axonopathy, denervation muscle 
atrophy and accelerated sarcopenia which confers significant locomotor deficits (Flood et al., 
1999; Shefner et al., 1999; Muller et al., 2006). It seems that a loss-of-function cannot be 
completely excluded from a pathogenic mechanism of all SOD1 mutants. 
Similarly with other diseases, increased dosage of SOD1 was also tested. Transgenic 
mice overexpressing human SOD1WT were generated (Epstein et al., 1987). This model was 
characterized by hypotonia, hindlimb neuromuscular pathology (Avraham et al., 1988, 
Avraham et al., 1991; Rando et al., 1998), muscular dystrophy, vacuolar pathology, axonal 
Figure 3 | Mutations causing ALS. So far, 166 mutations have been linked to ALS throughout the 153 SOD1 
aminoacid polypeptide length (Adapted from Cleveland & Rothstein, 2001). 
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loss and motor neuron degeneration were described in spinal cords of aged animals (Dal 
Canto & Gurney, 1995; Jaarsma et al., 2000). No lines of transgenic human SOD1WT mice 
have succumbed to ALS symptoms to date, although animals appear to undergo prolonged 
subclinical motor neuron degeneration. 
 
1.4.2. SOD1 mutant transgenic model 
In ALS research, the mainstay has been a mouse that bears the human gene for the 
known mutation of SOD1 associated with familial ALS. The mouse bearing this kind of 
mutated gene was the first laboratory model clearly linked to ALS based on a known cause 
of the disease. The interpretation of this particular model requires some consideration of 
wild-type SOD1 overexpressing and knockout mice, described above (Turner & Talbot, 
2008). The discovery of SOD1 mutations in FALS was promptly followed by the generation of 
transgenic mice constitutively expressing mutant human SOD1 genes (Gurney et al., 1994). 
These transgenic constructs typically involve 12-15 kb human genomic fragments encoding 
SOD1 (harboring a 93 Gly – Ala substitution, from which SOD1G93A designation derives) 
driven by the human endogenous promoter and regulatory sequences. Despite vast 
differences in transgene copy number, steady-state transcript and protein levels, dismutase 
activity and neuropathology, the mutations induce fatal symptoms strongly indicative of ALS 
with different disease latencies and progression rates. Crucially, the disease phenotype of 
transgenic mice expressing hSOD1 mutants on a background of endogenous enzyme 
argued for a dominant gain-of-function mechanism in toxicity (Gurney et al., 1994). 
Transgenic SOD1G93A mice are principally used in ALS research because of abundant 
expression, stability and activity in the CNS. Mice develop hindlimb tremor and weakness at 
around 3 months detected by locomotor deficits progressing to hyper-reflexia, paralysis and 
premature death after 4 months (Gurney et al., 1994). Pathologically, neuromuscular 
junctions degenerate around 47 days which appears selective for fast-fatiguable axons (Pun 
et al., 2006). Proximal axonal loss is prominent by 80 days coinciding with motor impairment 
and a severe (50%) dropout of lower motor neurons, is evident at 100 days (Fisher et al., 
2004). This retrograde sequence of neurodegeneration has led to an attractive proposal that 
ALS may be a distal axonopathy, described later. 
At present, 12 different human SOD1 mutants have been expressed in mice. These 


















1.5. Pathogenic mechanisms of ALS 
Despite the fact that a number of genes have now been linked to ALS, the exact 
pathogenic mechanisms are still largely unclear. Our current understanding of the pathology 
of ALS is largely based on studies of ALS-associated gene mutations. Because the clinical 
and pathological profiles of sporadic and familial ALS are similar, it can be predicted that 
insights from studies of ALS-causing gene mutations apply to sporadic ALS. The 
mechanisms underlying neurodegeneration in ALS are multifactorial and operate through 
inter-related molecular and genetic pathways (figure 5). Specifically, neurodegeneration in 
ALS might result from a complex interaction of several factors including: cytoplasmic 
misfolded protein aggregates, glutamate excitotoxicity, mitochondrial dysfunction, oxidative 
stress, disruption of axonal transport process, endoplasmic reticulum stress and 
neuroinflammation. Other factors equally important, which are not going to be described in 
detail, are endossomal trafficking dysregulation, transcription and RNA processing 
Figure 4 | Time course of clinical and neuropathological events in the high copy number transgenic 
SOD1G93A mice. Mice develop hindlimb tremor, weakness and locomotor deficits at about 3 months which is 
preceded by distal synaptic and axonal degeneration. This progresses into fatal paralysis about 1 month later 
concomitant with spinal motor neuron loss and reactive gliosis. A sequence of mutant SOD1 aggregation into 
insoluble protein complexes (IPC), inclusion bodies modified by the ubiquitin-proteasome system (UPS) and 
subcellular degeneration in motor neurons may underlie the phenotype. (extracted from Turner & Talbot, 2008). 
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impairements and the role of non-neuronal cells (Boillée et al., 2006; Dion et al., 2009; 
Redler & Dokholyan, 2012). 
 
1.5.1. Protein misfolding and aggregation 
Protein misfolding and aggregation are prominent features of ALS. Aspects of toxicity 
can arise either through aberrant chemistry, mediated by the misfolded aggregated mutants, 
or through loss or sequestration of essential cellular components; for example, by saturating 
the protein-folding chaperones and/or the protein-degradation machinery. Consistent with the 
latter, the aggregates are intensely immunoreactive with antibodies to ubiquitin, a feature 
common not only to all instances of disease in mice, but also to many human examples 
(Clement et al., 2003; Henkel et al., 2006; Cassina et al., 2008). Partial inhibition of the 
proteasome is sufficient to provoke large aggregates in non-neuronal cells that express 
SOD1 mutants, leading to the proposal that proteasome activity could be limiting by 
combating such aggregates and moreover, that undue proteasomal attention to aberrantly 
folded forms of SOD1 could compromise the removal of even more important components 
(Guo et al., 2003).  
Figure 5 | Schematic evolution of motor neuron degeneration during the course of SOD1 mutant ALS 
disease. Four stages are defined (normal, early phase, symptomatic, and end stage). Toxicity is non-cell-
autonomous, produced by a combination of damage incurred directly within motor neurons that is central to 
disease initiation and damage within non-neuronal neighbors, including astrocytes and microglia, whose actions 
amplify the initial damage and drive disease progression and spread. Selective vulnerability of motor neurons to 
ubiquitously expressed mutant SOD1 is determined by the unique functional properties of motor neurons (e.g., 
they are very large cells with large biosynthetic loads, high rates of firing, and respond to glutamate inputs) and 
damage to their supporting cells in the neighborhood. (extracted from Boillée et al., 2006). 
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1.5.2. Mitochondrial dysfunction and oxidative stress 
Mitochondria, have developed defenses to detoxify superoxide (O2•-) generated by the 
respiratory chain, a highly reactive molecule that contributes to oxidative stress and has been 
implicated in a number of diseases and aging (Turrens,1997; Barja, 1999). Multiple studies 
have shown that oxidative stress interacts with, and potentially exacerbates, other 
pathophysiological processes that contribute to motor neuron injury, including excitotoxicity 
(Rao & Weiss, 2004), mitochondrial impairment (Duffy et al., 2011), protein aggregation 
(Wood et al., 2003), endoplasmic reticulum stress (Kanekura et al., 2009), and alterations in 
signaling from astrocytes and microglia (Sargsyan et al., 2005; Blackburn et al., 2009). The 
most important are the Cu/Zn-superoxide dismutase (SOD1) and the manganese superoxide 
dismutase (Mn-SOD or SOD2). Age-related diseases, like neurodegenerative diseases, are 
associated with increased mitochondrial production of O2•- and H2O2. In ALS, there are 
evidences that these two reactive oxygen species (ROS) can generate highly reactive 
radicals, like OH•, which will modify all kinds of macromolecules including lipids (Shibata et 
al., 2001), proteins (Shaw et al., 1995), nuclear and mitochondrial DNA (Fitzmaurice et al., 
1996), and RNA species (Beal, 2005; Chang et al., 2008). Defective respiratory chain 
function associated with oxidative stress has also been found in tissue from patients with 
ALS at earlier stages of the disease. Dysfunction of components of the mitochondrial 
respiratory chain is also evident in the spinal cord of SOD1G93A transgenic mice at disease 
end stage (Mattiazzi et al., 2002). Furthermore, mutant SOD1 insoluble aggregates could 
directly damage the mitochondrion through: swelling, with expansion and increased 
permeability of the outer membrane and intermembrane space, leading to release of 
cytochrome c and caspase activation; inhibition of the translocator outer membrane (TOM) 
complex, preventing mitochondrial protein import; and aberrant interactions with 
mitochondrial proteins such as the anti-apoptotic BCL2 (Pasinelli & Brown, 2006; Ferraiuolo 
et al., 2011). 
 
1.5.3. Excitotoxicity 
Excitotoxicity, results from excessive influx of calcium cations through the over-
stimulation of post-synaptic glutamate receptors which may be caused by increased synaptic 
levels of glutamate, or by increased sensitivity of the post-synaptic neuron energy 
homeostasis or glutamate receptor expression. This increase of calcium can activate 
enzymes such as phosphatases, proteases, lipases and endonucleases, causing protein and 
lipid alterations in cell membranes, generation of ROS, and mitochondrial damage and 
dysfunction (Corona et al., 2007). Decreased levels of the glutamate transporter EAAT2 
(excitatory aminoacid transporter 2) are found in both human patients and in mutant SOD1 
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transgenic rodents (Rothstein et al., 1995). Thus, excitotoxicity may be involved in 
modulation of disease progression. 
 
1.5.4. Impaired axonal transport 
Motor neurons are highly polarized cells with long axons, and axonal transport is 
required for delivery of essential components, such as RNA, proteins and organelles, to the 
distal axonal compartment, which includes synaptic structures at the neuromuscular junction 
(NMJ). The main machinery for axonal transport uses microtubule-dependent kinesin and 
cytoplasmic dynein molecular motors, which mediate transport towards the NMJ 
(anterograde transport) and towards cell body (retrograde transport), respectively. Defects in 
either supply or clearance of material within an axon can lead to neuronal death. Axonal 
transport becomes impaired due to neurofilament disorganization via activation of protein 
kinases that phosphorylate neurofilament proteins (Pasinelli & Brown, 2006). 
 
1.5.5. Endoplasmic reticulum stress 
ER stress is an important pathway to cell death in ALS (Atkin et al., 2006; Atkin et al., 
2008), and is triggered very early in SOD1G93A transgenic mice (Saxena et al., 2009). ER 
stress is triggered when misfolded proteins accumulate within the ER lumen, inducing the 
unfolded protein response (UPR). Although the initial phases of the UPR aim to promote cell 
survival, prolonged or severe ER stress triggers the apoptotic phase of the UPR. Up-              
-regulation of the three UPR sensor proteins, PERK, ATF6 and IRE1, have been observed 
both at the symptom onset and at disease end stage of SOD1G93A transgenic mice, implying 
the involvement of ER stress in disease mechanisms (Atkin et al., 2006; kikuchi et al., 2006). 
The ER chaperone, protein disulphide isomerase (PDI), was found to co-localize with mutant 
SOD1 inclusions in both cellular and animal models of ALS and overexpression of PDI 
decreased mutant SOD1 aggregation, ER stress, and apoptosis (Walker et al., 2010). 
	  
1.5.6. Neuroinflamation 
Neuroinflammation is characterized in ALS by the appearance of reactive microglial 
and astroglial cells (Neusch et al., 2007; Van de Bosch et al., 2008), suggesting a non-cell 
autonomous process (Clement et al., 2003). In ALS, reactive astrocytes produce nitric oxide 
and peroxynitrite, and trigger mitochondrial damage and apoptosis in motor neurons 
(Cassina et al., 2008). Astrocytes may also contribute to damage motor neurons through 
excitotocicity. Furthermore, microglial cells are reported to be activated in the brain and 
spinal cord of patients with ALS, as well as mutant SOD1 transgenic mice. In fact activated 
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microglia were detected before motor neuron loss (Henkel et al., 2006). Damage within 
motor neurons is enhanced by injury from microglial cells via an inflammatory response that 
accelerates disease progression (Barbeito et al., 2004). 
 
1.6. Where does ALS begin? 
Despite Charcot’s initial observation of concomitant UMN and LMN pathological 
changes in ALS, the question of where ALS begins has not been established. Resolution of 
this question might enhance the understanding of the pathophysiology of ALS and has 
diagnostic and therapeutic importance (Meininger, 2011). Two theories have been proposed 
to explain which are the initial steps of ALS disease but more importantly where do they take 
place. The “dying-forward” hypothesis proposes that ALS is mainly a disorder of 
corticomotoneurons mediating anterograde degeneration of anterior horn cells. Support to 
this hypothesis includes: 
- Transneuronal degeneration in ALS is an active excitotoxic process in which live but 
dysfunctional corticomotoneurons, originating in the primary motor cortex, drive the anterior 
horn cell into metabolic deficit. When this is marked, it will result in more rapid and 
widespread loss of lower motor neurons (reviewed here Eisen & Weber, 2001). 
- Expression of SOD1G93A mutation induces energy dysfunction in discrete CNS motor 
regions long before motor neuron degeneration occurs (Browne et al., 2006). 
- Asymptomatic 60 day-old mice have lost approximately 9%, 12% and 14% of their 
corticospinal, bulbospinal and rubrospinal projections, respectively. 90 day-old mice that 
display the first clinical signs have lost approximately 30%, 33% and 33% of their 
corticospinal, bulbospinal and rubrospinal projections, respectively. Mice aged 110 days that 
have severe clinical signs, have lost approximately 53%, 41% and 43% of their corticospinal, 
bulbospinal and rubrospinal projections, respectively. (Zang & Cheema, 2002). 
The prevailing and best documented proposal however, is the “dying-back” hypothesis 
in which motor neuron loss in ALS involves retrograde degeneration within the muscle cells 
or at the NMJ. Support for the dying-back hypothesis includes: 
- A quantitative analysis demonstrating denervation at the NMJ by day 47, followed by 
severe loss of motor severe loss of motor axons (approximately 60%) from ventral roots 
between days 47 and 80, and loss of α-cell bodies from the lumbar spinal cord after day 80 
(Fisher et al., 2004). 
- Transgenic mice with skeletal muscle-restricted expression of hSOD1 gene develop 
neurologic and histopathologic phenotypes consistent with ALS. Muscle restricted expression 
is sufficient to cause dismantlement of NMJ and distal axonopathy (Dobrowolny et al., 2008, 
Wong & Martin, 2010). 
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- Magnetic Resonance Imaging (MRI) studies showed a significant reduction in muscle 
mass that parallels reduction in fiber diameter and muscle atrophy from week 8. Evidences of 
neurodegeneration in the brainstem detected only from week 10 (Marcuzzo et al., 2011). 
 
2. The motor nervous system 
The somatic portion of the nervous system is composed of two major types of nerve 
cells which connect the spinal cord to the periphery (figure 6). These are primary sensory 
neurons (or afferent neurons), which relay input from the periphery to the spinal cord, and 
spinal cord motor neurons (or efferent neurons) which convey motor outflow from the spinal 
cord to the periphery. Motor neurons can be divided in two groups: UMN, which originate in 
the motor region of the cerebral cortex or the brain stem and carry motor information down to 
the final common pathway, and LMN, connecting the brainstem and spinal cord to muscle 
fibers. Axons of spinal cord motor neurons pass to the periphery to innervate striated muscle. 
Even for most other reflexes, such as the withdrawal reflex, there is at least one other neuron 
(an interneuron - Renshaw cells) interposed in the circuit (Kandel et al., 2000; Marieb & 
Hoehn, 2007). 
Skeletal muscle is a form of striated muscle tissue existing under the control of the 
somatic nervous system. Some examples of this type of muscle are respiratory muscles and 
















2.1. Motor neurons and neuromuscular synaptic transmission 
The phenomenon of neuronal cross-talk is often termed neurotransmission and it is 
mediated by neurotransmitters. Neurotransmitters are endogenous chemicals that transmit 
signals from a neuron to a target cell across a synapse allowing the brain to communicate 
with the rest of the body (Marieb & Hoehn, 2007). 
(http://davidsciencestuff.tripod.com/id1.html) 
Figure 6 | Somatic Component of the 
Peripheral Nervous System. The 
peripheral nervous system can be 
subdivided into somatic and autonomic 
components. The somatic nervous 
system contains motor nerves and 
sensory nerves innervating skin and 
muscle. The soma (cell bodies) of motor 
nerves and sensory nerves are located 
in the gray matter of the anterior horn of 




The nerve terminal is responsible for neurotransmitter release and stores it in small, 
uniformly sized vesicles. Synapses between motor neurons typically use glutamate or GABA 
as their neurotransmitters, while the NMJ uses acetylcholine exclusively. Glycine is also 
present in the interneurons of the spinal cord. Arrival of an action potential at the motor 
neuron ending leads to an instant opening of voltage-gated Ca2+ channels with a subsequent 
abrupt increase in intracellular calcium concentration (Fagerlund & Eriksson, 2009; Martyn et 
al., 2009). This increased calcium concentration triggers a cascade of intracellular signaling 
events leading neurotransmitter-containing vesicles to migrate, dock, fuse to the surface of 
the nerve, rupture and discharge the specific neurotransmitter through the synaptic cleft to 
the receptive post-synaptic component, either a neuron or the NMJ. The energy required for 
these processes is generated by a large population of mitochondria present in the cytoplasm. 
At the NMJ (figure 7) the nicotinic acetylcholine receptors (nAChRs) in the sarcolemma, 
activated by the released acetylcholine, respond by opening their channels for influx of 







Purinergic research has been demonstrated to be potentially fruitful on 
neurodegenerative disorders such as ischemia, neuropatic pain, multiple sclerosis, 
Parkinson’s, Alzheimer’s and Huntington’s diseases (Burnstock, 2008a,b) and might 
accordingly provide novel clues also for ALS. The validation that purinergic research could 
indeed meet ALS comes from the general notions that 1) microglia, astrocytes and 
degenerating neurons, commonly release and promptly respond to both ATP and adenosine; 
2) extracellular ATP secreted at high concentrations is toxic to neurons and activates 
microglia and astrocytes, being thereafter degraded to adenosine creating 
neuroinflammation; 3) neuron toxicity, microglia and astrocyte activation are all common 
(adapted from http://faculty.pasadena.edu) 
Figure 7 | Structure of the Neuromuscular 
Junction. Schematic representation of the adult NMJ 
with the three main components: pre-synaptic nerve 
terminal, synaptic cleft and post-synaptic membrane. 
Stimulation of a motor nerve results in the release of 
acetylcholine from vesicles at the pre-synaptic 
membrane; acetylcholine diffuses and binds to post-
synaptic receptors, producing depolarization of the 
sarcolemma and leading to an action potential. 
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features to ALS (Volonté et al., 2011). Adenosine is a ubiquitous nucleoside, present and 
being released from apparently all cells, including neurons and glia. It comprises a molecule 
of adenine attached by a glycosidic bound to a ribose sugar molecule. Perhaps as a result of 
their ubiquitous nature, purines have also evolved as important molecules for both 
intracellular and extracellular signaling, roles that are distinct from their activity related to 
energetic metabolism, as adenosine diphosphate (ADP) and adenosine triphosphate (ATP), 
and synthesis of nucleic acids (Khakh and Burnstock, 2009). 
Unlike ATP, which may function as a neurotransmitter in some brain areas, adenosine 
is neither stored nor released as a classical neurotransmitter. It does not accumulate in 
synaptic vesicles, being released from the cytoplasm into the extracellular space in a calcium 
independent process through a nucleoside transporter. The adenosine transporters also 
mediate adenosine reuptake, being the direction of the transport dependent on the 
concentration gradient at both sides of the membrane. As it is not exocytotically released, 
adenosine behaves as an extracellular signalling molecule that modulates synaptic 
transmission. Using G-protein coupled mechanisms, that not only lead to changes in second 
messenger levels but also to regulation of ion channels, such as calcium and potassium 
channels, adenosine modulates neuronal activity, pre-synaptically by inhibiting or facilitating 
transmitter release, post-synaptically by affecting the action of other neurotransmitters and 
non-synaptically by hyperpolarizing or depolarizing neurons and/or exerting non-synaptic 
effects (e.g. on glial cells). Adenosine, therefore, belongs to the group of neuromodulators, 
endogenous substances released at the synaptic cleft that influence the release (pre-
synaptic modulation) or the action (post-synaptic modulation) of the neurotransmitters 
(Sebastião & Ribeiro, 2000; Ribeiro & Sebastião, 2010). 
 
3.1. Adenosine receptors 
Adenosine receptors are a class of specific purinergic receptors with adenosine as the 
endogenous ligand. There are four adenosine receptor subtypes among vertebrates, which 
have been cloned and characterized to date (table 2): adenosine A1, A2A, A2B and A3 
receptors that belong to the G-protein coupled receptors (GPCRs) family. (Fredholm et al., 
1994, Fredholm et al., 2001). These receptors are also known as P1 receptors, from the P1 
(adenosine selective)/P2 (ATP selective) nomenclature (Burnstock, 1978). A1R and A3R are 
coupled to Gi/o inhibitory proteins while A2AR and A2BR are coupled to Gs excitatory proteins 
(Linden, 2001; Ribeiro et al., 2002). Neuromodulation by adenosine is exerted through 
activation of high-affinity adenosine receptors (A1 and A2A) which are probably of 
physiological importance, and of low-affinity adenosine receptors (A2B), which might be 
relevant in pathological conditions. The A3R is a high-affinity receptor in humans, but it has a 
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low density in most tissues (Ribeiro & Sebastião, 2010). However, much of the data on 
coupling to other G-proteins are from transfection experiments and it is not known if such 
coupling is physiologically important. There are evidences that A2AR may be coupled to 
different G-proteins in different areas (Kull et al., 2000). Other authors (Auchampach et al., 




3.2. Adenosine receptors distribution and interactions 
Within the CNS, the A1R has the highest expression in the brain cortex, cerebellum, 
hippocampus and dorsal horn of spinal cord, coupled to activation of K+ channels (Trussell & 
Jackson, 1985) and inhibition of Ca2+ channels (Macdonald et. al., 1986), both of which 
would inhibit neuronal activity. The A2AR is expressed at high levels in only a few regions of 
the brain (striatum has the higher expression) and is primarily linked to the activation of 
adenylate cyclase (Sebastião & Ribeiro, 1996). The A2BR, which also activates adenylate 
cyclase, is thought to be fairly ubiquitous in the brain (Dixon et al., 1996), but it has been 
difficult to link this receptor to specific physiological or behavioral responses (Feoktistov & 
Biaggioni, 1997). The A3R is also somewhat poorly characterized, but apparently has 
intermediate levels of expression in the human cerebellum and hippocampus and low levels 
in most of the brain (Fredholm et al., 2001). It has been reported to uncouple A1 and 
metabotropic glutamate receptors via a protein kinase C–dependent mechanism (Dunwiddie 
et al., 1997; Macek et al., 1998), and thus, one of its functions may be to modulate the 
activity of other receptors. Both A1 and A2A receptors are predominantly, but not exclusively, 




located pre-synaptically (Rebola et al., 2003; Baxter et al., 2005; Rebola et al., 2005a; 
Rebola et al., 2005b). Previous evidence indicates that A1R and A2AR may be co-localized in 
the same nerve terminals (Correia-de-Sá et al., 1991; Lopes et al., 1999a; Rebola et al., 
2005b; Pousinha et al., 2010). Moreover, both receptors were shown to form a heteromeric 
complex in co-transfected cultured cells (Ciruela et al., 2006). It is believed that A1R or A2AR 
are preferentially activated as a function of the source and amount of adenosine (Sebastião 
& Ribeiro, 2009). A1R are preferentially activated by adenosine generated intracellularly, 
released through adenosine transporters, and A2AR are activated preferentially by adenosine 
generated extracellularly (Cunha et al., 1996), due to the action of ectonucleotidases upon 
ATP release. The relative density of A1R or A2AR adenosine receptors in sub-regions of the 
same brain area may differ. Whenever the two receptors co-exist, we can ask about their 
relative importance, i. e. the hierarchy of one receptor with respect to the other. This may 
change with neuronal activity, the age and even on other molecules that are in the vicinity of 
the site of action and that may be relevant for the production or inactivation of the ligand 
(Sebastião & Ribeiro, 2009). High frequency of neuronal firing favours ATP release (Cunha 
et al., 1996) and adenosine formed from released adenine nucleosides seems to prefer A2AR 
activation (Cunha et al., 1996) which may be due to the geographical distribution of ecto-5-
nucleotidases and A2AR. A2AR activate adenosine transport, which in the case of high 
neuronal activity and ATP release is in the inward direction. This induces a decrease in 
extracellular adenosine levels and a reduced ability of A1R to be activated by endogenous 
extracellular adenosine. By themselves, A2AR are able to attenuate A1AR activation (Cunha 
et al., 1994) which may further contribute to a decreased activity of A1R receptors under high 
frequency neuronal firing. The ability of adenosine receptors to inhibit synaptic transmission 
is attenuated by the protein kinase C (PKC) activation (Sebastião & Ribeiro, 1990) and a 
similar mechanism appears to be involved in the A2AR-mediated attenuation of A1R 
responses (Lopes et al., 1999). Adenosine receptors are also present in the peripheral 
nervous system, either autonomic or somatic, especially at the motor nerve endings. There 
are reports that human and rat skeletal muscle express both mRNA and protein of adenosine 





The present work was designed to determine the effect of the SOD1G93A mutation on 
the expression of A1 and A2A adenosine receptors of the ALS transgenic mouse model for the 
human gene SOD1, through disease progression (pre-symptomatic and symptomatic 
phases). As described above ALS’s primary hallmark is the degeneration of the upper motor 
neurons of the motor cortex and of the lower motor neurons, which extend through the 
brainstem and spinal cord to innervate skeletal muscles at the neuromuscular junction level 
(Boilléee et al., 2006). Therefore, three different tissues were analyzed, i.e. the motor cortex, 
spinal cord and phrenic nerve-diaphragm (herein referred as diaphragm). This approach 
covered both CNS and PNS adenosine receptor expression. Adenosine is known to 
modulate various physiological functions of most tissues, including skeletal muscles (Hespel 
& Richter, 1998). This is the main reason why adenosine is the target of this work. 
Therefore, to achieve this main goal I formulated three specific questions: 
 
Aim 1: Are the protein levels of A1 and A2A receptor changed in the motor cortex, spinal 
cord and the neuromuscular junction throughout disease progression? To answer this 
question the immunoblotting technique was used. 
 
Aim 2: Are the mRNA levels of A1 and A2A receptor altered in the neuromuscular 
junction throughout disease progression? To answer this question quantitative Real-Time 
PCR technique was used. 
 
Aim 3: Is the primary pathological feature, regarding the expression of adenosine 
receptors, observed in the central or in the peripheral nervous system? Specifically, I tried to 
establish throughout disease progression, if the first event related to adenosine receptor 
alterations occurs in the motor cortex, spinal cord or at the neuromuscular junction level. 
 
 
This work is part of a project (PTDC/SAU-NEU/101752/2008) funded by Fundação 





MATERIALS & METHODS 
	  
1. Breedings and housbandry 
Transgenic B6SJL-Tg(SOD1-G93A)1Gur/J males and wild-type B6SJLF1/J females 
were purchased from Jackson Laboratory (USA; Stock No. 002726 and 100012, 
respectively) and a colony was established at the rodent facility (Instituto Medicina 
Molecular). Since transgenic female line has a very high incidence of non-productive matings 
(Leitner et al., 2009), mice were maintained on a background B6SJL by breeding transgenic 
males with non-transgenic females in a rotational scheme. Animals were handled according 
to European Community Guidelines and Portuguese Law on Animal Care (2010/63/UE). At 
time of weaning, littermates were identified through ear punching and separated in different 
cages according to their gender. This system is a permanent procedure that attributes to 
each hole a number and allows individual identification of mice. Moreover, this method does 
not require anesthesia, guarantee animal welfare, and the tissue removed by the ear punch 
can be used for DNA analysis, phasing out the requirement of an additional procedure for 
genotyping (Costa & Antunes, 2010). All animals were housed 4-5 mice per cage, under a 
12h light/12h dark cycle, and received food and water ad libitum. 
 
2. Mice genotyping 
Using the tissue removed by ear punching, as described above, the mice DNA was 
isolated by adding TDB (50 mM KCl, 10 mM Tris-HCl pH=9.0, 0.1% Triton X-100, 0.15 
mg/mL proteinase K) followed by an overnight incubation at 56⁰C. Additionally a heat 
proteinase K inactivation was performed during 15 min at 95⁰C. After a 2 min centrifugation to 
remove debris a PCR reaction was prepared. Primers against interleukin-2 precursor 
(internal positive control) and human SOD1 transgene were raised (see annexe II, table 7). 
For a total of 25 µL the following components were added per sample: 0,2 mM dNTP mix, 
10X DreamTaq Buffer containing MgCl2, 1.5 U DreamTaq DNA polymerase (Fermentas®), 
1.33 µM of the transgene SOD1 primer, 0.75 µM of the control primer, water and 200-500 ng 
DNA template (BioRad® C1000 Thermal Cycler, see annexe I, table 4 for PCR conditions). 
Both PCR products and DNA ladder (1 kb gene ruler, Fermentas®) were loaded in a 2% 
agarose gel and an electrophoretic migration took place. With a Red Safe dyed gel it was 
possible to inspect bands in a transiluminator (Molecular Imager® Gel Doc™ XR System) and 
distinguish between wild-type SOD1 individuals and human SOD1 transgenics. 
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3. Tissue extraction and dissection 
Male or female, wild-type and transgenic, F2 mice (4-6 and 13-14 weeks old) were 
anesthetized under isoflurane atmosphere before being decapitated. The brain was rapidly 
removed from the brain cavity and dissected free in ice-cold PBS 1X (137 mM NaCl, 2.7 mM 
KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4) in order to separate the motor cortex (rich 
in A1R) from the striatum (rich in A2AR) to avoid contamination. Additionally, the spinal cord 
and the diaphragm were extracted. The different tissues were either homogenized or 
separately frozen at -80⁰C until further use, as described below. 
 
4. Protein quantification 
4.1. Total protein homogenates 
Frozen tissue (cortex, striatum, spinal cord and diaphragm) was placed in 800 µL of 
RIPA buffer (1 M Tris pH 8.0, 0.5 M EDTA pH 8.0, 5 M NaCl, 0.1% SDS, 10% NP-40, 50% 
Glycerol), supplemented with protease inhibitors (RocheTM tablet and PMSF were added just 
prior to use), and homogenized in a Potter-Elvehjem homogenizer with a Teflon piston. The 
samples were then centrifuged at 3.5 rpm (1000 x g) during 10 minutes at 4⁰C, the 
supernatant was collected and corresponds to the whole tissue lysate. Protein was quantified 
using the BioRadTM Dc Protein assay Kit based on Lowry (1951), due to the high levels of 
detergents in the lysis buffer, by measuring the absorbance at 750 nm. 
	  
4.2. Gel electrophoresis and immunoblotting 
In order to assess the protein levels of A1 and A2A adenosine receptors in the motor 
cortex, spinal cord and in the diaphragm throughout disease progression the immunoblotting 
technique was used. After homogenate preparation and protein quantification, the 
appropriate volume of each sample (corresponding to 30 µg and 50 µg of protein to A1R and 
A2AR quantification, respectively) was diluted in water and loading buffer 5X (350 mM Tris 
HCl, 30% Glycerol, 10% SDS, 600 mM DTT and 0.012% Bromophenol blue, pH 6.8) 
performing a total volume of 25 µL to apply per lane. The striatum (5 µg) was used as 
positive internal control for A2AR due to its high content in this adenosine receptor. The cortex 
was used as positive control for A1R since it has high levels of this protein. As endogenous 
control, α-tubulin was used because it proved to be a reliable reference control. Prior to 
loading, the samples were boiled at 95⁰C for 5 minutes. Under reducing and denaturing 
conditions an electrophoretic migration took place, with both molecular weight marker and 
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samples, in a 10% resolving (and 5% stacking) gel concentration. A standard running buffer 
1X (25 mM Tris Base, 190 mM Glycine and 0.1% SDS) was used. Submerged in transfer 
buffer 1X (25 mM Tris Base, 190 mM Glycine and 20% Methanol), the separated gel proteins 
were then transferred to PVDF membranes, through a 250 mA electrical current for 90 
minutes. A Ponceau Red staining followed in order to check for success of transfer 
confirming that no air bubbles have formed between the gel and membrane. At this point 
membranes were cut into pieces separating above α-tubulin proteins from the receptor ones. 
Membranes were blocked with 5% non-fat dry milk for 1 hour, washed with TBS-T (200 nM 
Tris Base, 1.5 M NaCl and 0.1% Tween-20, pH 7.6) and incubated with primary antibodies 
overnight at 4⁰C. Primary antibodies were diluted in 3% BSA, 0.02% NaN3 and TBS-T. After 
washing again for 30 minutes, the membranes were incubated with secondary antibody, for 1 
hour at room temperature, and washed again (see table 1 for antibodies information). Finally, 
a chemoluminescent detection method was performed with ECL western blot detection 
reagent (GE HealthcareTM) using X-Ray films (FujifilmTM). Western blots densitometry was 
determined with Image J software and normalized to the respective α-tubulin band density. 
ImageJ Gel analyzer options: Uncalibrated OD; Inverted Peaks; Plot lanes (ImageJ v.1.47c, 
Wayne Rasband, National Institutes of Health, USA) (according to Miller, 2010; McLean, 
2011). 
Table 3 | Antibodies used in this study. Primary and secondary antibodies and related conditions used in the 
immunoblotting experiments for individual proteins. All primary antibodies were diluted in 3% BSA with 0.02% 
NaN3 and secondary antibodies in 5% non-fat dry milk. 
 
5. mRNA quantification 
5.1. Total RNA homogenates 
Frozen tissue (diaphragm) was placed in 1000 µL QIAzol Lysis Reagent (according to 
QuiagenTM RNeasy Lipid Tissue Mini Kit protocol) and homogenized in a Potter-Elvehjem 
homogenizer with a Teflon piston. The subsequent steps were followed from the same 
protocol and total RNA was eluted in 40 µL RNase-free water supplied. The concentration of 
total RNA was determined by measuring the absorbance at 260 nm in NanoDrop ND-1000 
(Thermo ScientificTM). 
Protein Predicted protein size Primary antibody Animal Dilution 
Secondary 
antibody Dilution 











A2AR 42 kDa 
UpstateTM 
(05-717) 
Mouse 1:1000 1:10000 
α-Tubulin 50 kDa AbcamTM (ab4074) Rabbit 1:20000 1:20000 
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5.2. cDNA synthesis and qRT-PCR 
Quantitative Real-Time PCR technique was used to evaluate the mRNA expression 
levels of A1 and A2A adenosine receptors in the diaphragm throughout disease progression. 
cDNA was obtained using the SuperScriptTM First-Strand Synthesis System for RT-PCR 
(InvitrogenTM) according to manufacturer’s protocol. For a total volume of 20 µL in each 
reaction tube, the following components were mixed: 0.5 mM dNTP, Random hexamears (50 
ng), DEPC-treated water, 1X RT buffer, 5 mM MgCl2, 10 mM DTT, 25 U of SuperScriptTM II 
reverse transcriptase and 2-5 µg RNA template. Minus RT controls were performed for each 
sample, in which DEPC-treated water was added instead of SuperScriptTM II reverse 
transcriptase. The reverse transcription of all samples took place in Bio Rad C1000 Thermal 
Cycler (see annexe I, table 5). These PCR products were quantified through qRT-PCR in 
Rotorgene 6000 (QuiagenTM) using SYBR® Green master mix method (Applied 
BiosystemsTM). Specific primers against A1R, A2AR and β-actin DNA sequence (see annexe I, 
table 6) were used in this reaction. β-actin was used as a reference gene to normalize target 
gene results. For a total volume of 25 µL in each reaction tube, these components were 
added: 2x SYBR® Green master mix, 5 µM primer solution, water and cDNA template. Non 
Template Controls (NTC) were performed for each primer, in which DEPC-treated water was 
added instead of cDNA templates. 
In order to make valid comparisons between different samples it is important to 
determine the primer amplification efficiency. Ideally, amplification efficiencies for control and 
target primer should be roughly equal. However, the amplification efficiency for a specific pair 
of primers is affected by differences in primer binding sites, the sequence of the amplification 
product, and PCR product sizes, and thus should be determined experimentally. The 
efficiency equation is: 
E = 10(!!/!) − 1 
where E is the efficiency of the reaction and M refers to the slope of the plot of Ct value 
versus the log of the input template amount. A slope between −3.6 and −3.1 corresponds to 
an efficiency between 90% to 110% (which corresponds to a value of E between 0.9 and 1.1) 
(Fraga et al., 2008). The Ct (cycle threshold) is defined as the number of cycles required for 
the fluorescent signal to cross the threshold (i.e. exceeds background level). Ct levels are 
inversely proportional to the amount of target nucleic acid in the sample (i.e. the lower the Ct 
level the greater the amount of target nucleic acid in the sample). The results for β-actin and 
A2AR were calculated based in the efficiency obtained from calibration curve analysis (see 
annexe III) and determined for each target gene using serial dilutions (1:5) of cDNA of pre-
symptomatic diaphragm homogenate. The presented results are fold change values 
calculated with the Pfaffl equation (Pfaffl, 2001). Therefore, they reflect the difference in 
adenosine receptors mRNA expression between CTRL and SOD1 animals. Values equal to 
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1 (=1) are indicative of same CTRL and SOD1 expression; fold change above the unit (>1) 
mean that SOD1 has a higher expression in relation to the CTRL; and values below 1 (<1) 
mean that SOD1 has a lower expression when compared to CTRL. 
The Pfaffl equation to calculate fold change values (Pfaffl, 2001) is: 
 





in which Ct reference corresponds to the number of amplification cycles obtained in the qRT-
PCR for β-actin triplicates, and Ct target for target gene triplicates, both belonging to the 
same animal sample. β-actin fold change results were calculated considering the efficiency 
(E=1,01), slope (M=-3,288) and the correlation coefficient (R2=0,99) of the calibration curve. 
A2AR efficiency is 1,11, slope is -3,089 and correlation coefficient 0,99. For A1R, due to 
insufficient levels of mRNA expression in the diaphragm required to obtain a calibration 
curve, data from spinal cord experiments (laboratory results, unpublished data) were used. 
Efficiency for A1R calibration curve is 1,0, slope is -3,351 and correlation coefficient 0,99. 
Melting point analysis was always performed after each qRT-PCR run as a quality control 
step (Fraga et al., 2008). Melting point analysis is used to distinguish target amplicons from 
PCR artifacts such as primer-dimer or mis-primed products. Specificity is confirmed by the 
presence of a unique peak in the melting curve (see annexe III). 
6. Statistics 
For statistical evaluation of the data, Graphpad PRISM® 5 (San Diego, California, USA) 
software was used. To assess the significance for protein quantification between CTRL and 
SOD1 mice for each tissue, the Student’s t-test was used (with the Welch’s correction). The 
significance of diaphragm mRNA levels between the pre-symptomatic and suymptomatic 
phases were assessed with a Student’s t-test (with the Welch’s correction). The values 
presented, for protein and mRNA quantification, are mean ±SEM of n=5 experiments. Values 





Quantification of A1 and A2A receptor protein levels 
 
Regarding A1R protein levels in pre-symptomatic animals (figure 8A) there is no 
significant difference (t-test, p=0,8396) between wild-type mice (henceforward named as 
CTRL) and hSOD1G93A transgenic mice (now on referred as SOD1) for the motor cortex (CX). 
The same observation is true for the spinal cord (SC) and the diaphragm (DP) (t-test 
p=0,6383 and p=0,8984, respectively). Although not significant, slight differences are noted 
in the SC where SOD1 animals show a decrease in A1R protein expression. 
For the symptomatic phase (figure 8B) no significant difference in A1R is observed 
between SOD1 and CTRL mice for the CX (t-test, p=0,9974). For the SC an increase in A1R 
is registered for SOD1 mice, despite not statistically significant (t-test, p=0,5143). For the DP 





































































Pre-symptomatic (4-6w) Symptomatic (13-14w) A B 
Figure 8 | Immunoblot analysis of the expression levels of A1 adenosine receptor in control and hSOD1 
mutants. (A) Immunoreactivity of A1AR was performed in motor cortex, spinal cord and diaphragm homogenates 
of pre-symptomatic and (B) symptomatic animals. A1AR runs at ~37 kDa in the western blot. As a loading control 
α-tubulin was used (~55 kDa). Graphs represents the mean quantification of A1/tubulin intensity ratio of n=5. 
Error bars indicate the standard error and statistical comparison was performed by t-test. CTRL, wild-type 
control; SOD1, transgenic SOD1; CX, cortex; SC, spinal cord; DP, diaphragm. 
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With respect to A2AR protein expression in the pre-symptomatic animals (figure 9A) the 
CX shows an accentuated increase in SOD1 when compared to CTRL animals. However, 
this difference is not statistically significant (t-test, p=0,1560). For the other tissues, SC and 
DP, no significant are observed between SOD1 and CTRL animals (t-test, p=0,7083 and 
p=0,3724, respectively). 
Concerning the symptomatic animals (figure 9B), once again, the CX has the highest 
difference, although not significant (t-test, p=0,3409) with SOD1 showing a decreased 
expression of A2AR in relation to CTRL mice. For the other tissues, SC and DP, no significant 
differences are observed between SOD1 and CTRL mice (p=0,6722 and p=0,3305, 


































































Figure 9 | Immunoblot analysis of the expression levels of A2A adenosine receptor in control and 
hSOD1 mutants. (A) Immunoreactivity of A2AAR was performed in motor cortex, spinal cord and diaphragm 
homogenates of pre-symptomatic and (B) symptomatic animals. A2AAR runs at ~42 kDa in the western blot. As 
a loading control α-tubulin was used (~55 kDa). Graphs represents the mean quantification of A2A/tubulin 
intensity ratio of n=5. Error bars indicate the standard error and statistical comparison was performed by t-test. 
CTRL, wild-type control; SOD1, transgenic SOD1; ST, striatum; CX, cortex; SC, spinal cord; DP, diaphragm.  
	  
Pre-symptomatic (4-6w) Symptomatic (13-14w) A B 
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Quantification of A1 and A2A receptor mRNA levels 
 
The A1R mRNA expression in the diaphragm (figure 10) of pre-symptomatic SOD1 
animals is 1,2 in relation to CTRL which reflects no significant difference (t-test, p= 0,9138). 
For the symptomatic phase. SOD1 animals present a 1,6 fold change in A1 mRNA 
expression, but this increase in SOD1 mice is not statistically significant (t-test, p=0,4012). 
Furthermore, although not significant (t-test, p=0,3900), it is possible to observe that, A1R 
mRNA expression slightly increases in SOD1 mice through disease progression. 
Regarding A2AR mRNA expression in pre-symptomatic animals, it is possible to see a 
fold change of 1,0. This indicates that SOD1 are expressing A2AR as CTRL mice, so the 
differences at this phase of the disease are not significant (t-test, p=0,7713). For the 
symptomatic phase SOD1 mice show no significant difference (t-test, p=0,3638) in 
adenosine A2AR mRNA expression, with a fold change of 0,9. Moreover, there is no 




















Figure 10 | Quantitative RT-PCR analysis of the expression levels of A1 and A2A adenosine receptor in 
diaphragm for hSOD1 mutants throughout disease. mRNA of adenosine receptors expression was 
performed in whole diaphragm homogenates of pre-symptomatic and symptomatic animals. As an endogenous 
control β-actin was used. Graph represents the fold change (FC) values of normalized A1 and A2A/β-actin 
intensity ratio of n=5. Fold change values were calculated according to Pfaffl equation. If fold change value is 
equal to 1 (FC=1), it means that expression of SOD1 is the same as in CTRL animals. FC values higher (FC>1) 
than 1 mean a mRNA increased expression in SOD1 comparing to CTRL mice, and lower than 1 (<1) a 
decreased mRNA expression. Error bars indicate the standard error and statistical significance was performed 
by t-test analysis. PST, pre-symptomatic phase; ST, symptomatic phase. 





























Primary pathological feature, regarding the expression of adenosine receptors 
 
Results from this study (figure 11) indicate unaltered A1 receptor protein levels at the 
CNS and PNS through disease progression. However, there is an overexpression (not 
statistically significant) of A2A receptors in the cortex of pre-symptomatic mice and a 
decrease in the symptomatic phase. The A2A receptors are unaltered in the other tissues in 
both phases of the disease. The mRNA evaluation does not reveal significant alterations in 
both adenosine receptors during disease progression. Thus, regarding adenosine receptors 








Figure 11 | Schematic representation A1 and A2A adenosine receptor variation in the CNS and PNS of 






Amyotrophic Lateral Sclerosis related research offered only one drug with very modest 
disease modifying results. Then, it is urgent to identify specific biomarkers for the disease 
diagnostic and treatment targets. In this scenario, extracellular purines are powerful 
physiopathological molecules, signaling to most cell types and directing cell-to-cell 
communication networks. Their role has increasingly been recognized in several 
neurodegenerative and neuroinflammatory conditions such as ischemia, neuropatic pain, 
multiple sclerosis, Parkinson’s disease, Alzheimer’s disease and Huntington’s disease 
(Amadio et al., 2011). However, the involvement of adenosine receptors in ALS is still poorly 
understood. 
The results from this work show that A1 adenosine receptor protein levels are not 
altered in this particular model of ALS, at specific periods of the disease time course (pre-
symptomatic and early symptomatic). These results are consistent across all tested tissues 
from the CNS and PNS, i.e. motor cortex, spinal cord and phrenic nerve-diaphragm. A first 
suggestion immediately rises that the G93A mutation, in SOD1 gene, is not affecting any key 
pathways of A1 receptors expression like transcription, translation, protein migration, 
membrane integration and others. Contrary to our findings in ALS mice, Albasanz et al., 
(2007), observed that A1 receptor protein levels were increased in the cortex of Alzheimer´s 
disease patients. Therefore, it would be interesting, in the future, to evaluate if the function of 
these receptors is conserved in ALS. The registered oscillations (that are not statistically 
significant) can be explained by animals intrinsic variability or due to the number of replicas 
used. 
The A2AR protein expression is increased in the cortex of pre-symptomatic animals, but 
not in the other tissues (spinal cord and diaphragm). Up-regulation of A2A receptors was also 
found in the frontal cortex of Pick’s and Alzheimer’s disease patients (Albasanz et al., 2006, 
2007). Recent findings indicate a potential crosstalk between TNF receptors and A2A 
receptors in Parkinson´s Disease (Varani et al., 2010). According to these authors, high 
levels of TNF increase the expression of A2A receptors. TNF is related to neuroinflammation  
and neuronal damage and it is produced in higher levels by adult hSOD1G93A microglial cells 
(Boilléee et al., 2006). In the symptomatic phase, the results for the cortex of transgenic mice 
point to a down regulation of A2A receptors. However, these are unchanged in the spinal cord 
and diaphragm of these animals. Once again, the SOD1 mutation is not affecting receptor 
expression or transport, but it is not possible to know with this work if they are functionally 
active. 
Analysis of A1R and A2A mRNA expression in the diaphragm also show no differences 
in both phases of the disease, which is in accordance with the protein expression profile 
29 
	  
obtained for the diaphragm adenosine receptors. Alterations in the mRNA expression of 
adenosine receptors in the phrenic nerve are more critical to detect because transcription 
takes place at the C3-C5 spinal segments, which contain most of phrenic motor neurons 
somas. mRNA transcripts are then transported through the long axons by active transport 
through cellular cytoskeleton to the neuromuscular junction. Either mRNA and protein 
expression results are from total diaphragm homogenates, which means that we can be 
overanalyzing adenosine receptors in muscles and vasculature expression more than in 
phrenic nerve terminals. But, although some authors (Dixon et al., 1996; Lynge & Hellsten, 
2000) report that human and rat skeletal muscle express both mRNA and protein of 
adenosine receptors, their levels are low, especially in what concerns the A1 receptor. 
Results from our group (unpublished data) indicate that A1 and A2A receptor mRNA 
levels are also unaltered in the spinal cord of transgenic mice during disease progression. In 
the cortex, although the mRNA expression of A1 receptors is unchanged the mRNA levels of 
A2A receptors is significantly increased in the pre-symptomatic phase. These findings are in 
accordance with the protein level results obtained in this work for both adenosine receptors 
through disease progression. Interestingly, in their study on Alzheimer´s disease, Albasanz 
et al. (2007) found that the increased protein levels of both adenosine receptors were not 
associated with an increase in the mRNA levels. 
Taken together, results from this study and from our laboratory (unpublished data) 
indicate no alterations of A1 receptor protein or mRNA levels in SOD1G93A mice both in CNS 
and PNS during ALS progression. A1 receptor has long been known to mediate 
neuroprotection, mostly by blockade of calcium influx, which results in inhibition of glutamate 
release and reduction of its excitatory effects at a postsynaptic level (Dunwiddie & Masino, 
2001; Ribeiro et al., 2003; Fredholm et al., 2005; Stone, 2005). One of the pathological 
features of ALS is an excessive influx of Ca2+ during repetitive firing of glutamate receptors 
on motor neurons due to the loss of the EAAT2 glutamate transporter especially at the 
symptomatic phase (Boillée et al., 2006; Turner & Talbot, 2008). The unchanged levels of A1 
receptors point to a deficient neuroprotection by A1 receptors at this stage of the disease. 
This may be because the A1 receptors neuroprotective role is outweighed by the 
excitotoxicity caused by glutamate release. Another possible explanation is that, although the 
A1 receptors expression is unaltered their function to modulate synaptic transmission may be 
compromised. However, the role of A2A receptor in neuroprotection is not so clear, probably 
because of its lack of abundance in brain regions other than the striatum (Albasanz et al., 
2008). Data from the present study and from our laboratory (unpublished data) show that A2A 
receptor protein or mRNA levels in SOD1G93A mice are up-regulated in the cortex (CNS) but 
not in the spinal cord or phrenic nerve-diagphram (CNS/PNS) through ALS progression. 
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Adenosine A2A receptors can modulate the release of several neurotransmitters, such 
as acetylcholine, glutamate, and noradrenaline. The release of GABA might be either 
enhanced or inhibited by A2A receptor activation. Additional functions of these receptors 
include modulation of neuronal excitability, synaptic plasticity, as well as locomotor activity 
and behavior. The ability of A2A receptors to interact with other receptors such as adenosine 
A1 receptors, CGRP receptors, metabotropic glutamate receptors and nicotinic 
autofacilitatory receptors, increases the range of possibilities used by adenosine to interfere 
with neuronal function and communication (Sebastião & Ribeiro, 1996). Blocking A2A 
receptor function using antagonists or deleting the A2A receptor gene results in a decrease in 
the extent of neuronal damage in adult animals (Albasanz et al., 2006). Beneficial effects 
evoked by A2A receptor antagonists may be caused by blockade of presynaptic A2A receptors 
which are stimulatory on glutamate release (Abbracchio & Cattabeni, 1999). However, the 
mechanisms behind this neuroprotection remain unknown (Cunha, 2005).  
Considering our results, that A2A receptors have an up-regulated protein expression in 
the cortex of ALS SOD1 transgenic mice and that they are associated with neuronal damage, 
an increase in A1 receptor levels was expected as a neuroprotective compensatory 
mechanism of the system against A2A receptor effects, but this was not the case here. In fact, 
in their study on Alzheimer´s disease, Albasanz et al. (2007) found increased protein levels 
of both adenosine receptors connected with a functional increase in A1 and A2A receptor-
mediated response, but not with an mRNA expression increase. Processes associated with 
adenosine receptors functionality, like post-transcriptional and translational modifications, are 
beyond the scope of this work and cannot be predicted, i.e. even when the expression 
mechanisms are not altered further research is needed to unravel the adenosine receptors 
capacity to modulate synaptic transmission. However, some authors (e.g. Volonté et al., 
2011) have identified some SOD1 caused impaired molecular features such as aberrant 
axonal transport, cytoskeleton alterations, mitochondrial dysfunction, protein misfolding and 
aggregation and altered RNA metabolism that could compromise functional processes 
related to adenosine receptors neuromodulation. 
In conclusion, the major findings of this study indicate unaltered A1 receptor protein 
levels at the CNS and PNS through disease progression. However, there is an 
overexpression of A2A receptors in the cortex of pre-symptomatic mice and a decrease in the 
symptomatic phase, being unchanged in the other tissues at both phases of the disease. 
Thus, regarding adenosine receptors in ALS, the first changes seem to occur early in the 
disease at the CNS in A2A receptors. Since A2A receptor high expression can be found only in 
the cortex of ALS mice, I hypothesize that this work supports the dying forward theory which 
proposes that ALS originates primarily in the motor neurons of the cortex, i.e. it starts in the 
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Table 4 | Thermocycler PCR conditions for genotyping protocol. 
Step Temperature ºC Time Number of cycles 
Initial denaturation 94 3 min 1 
Denaturation 94 30 sec 
29 Annealing 62 30 sec 
Extension 72 30 sec 
Final Extension 72 10 min 1 
Storage 4 forever - 
 
Table 5 | Thermocycler cDNA sysnthesis protocol. (*) Add 2x reaction mix + Superscript II RT.  
RT - reverse transcriptase. 
Step Temperature, ºC Time Number of cycles 
RNA denaturation 65 5 min 1 
Pause (*) 4 2 min 1 
RNAaseOUT step 25 10 1 
Reverse transcription 42 50 min 1 
RT inactivation 70 15 min 1 
RNaseH 37 20 min 1 
Storage 4 forever - 
 
Table 6 | Rotorgene thermocycler conditions for qRT-PCR. 
 
  
Step Temperature, ºC Time Number of cycles 
AmpliTaq Gold DNA 
Polymerase activation 
95 10 min 1 
Denaturation 95 15 sec 
45 Annealing/Extension/Reading 
Cycling A Green 
60 25 sec 
Melting curve (72-95ºC) 
72 90 sec 1 





Table 7 | Primers used in this study for genotyping and qRT-PCR. (*) β-actin primers kindly provided by Tiago 
Outeiro laboratory. 
Primer type Sequence (5’ to 3’) Assay 
hSOD1 Forward CAT CAG CCC TAA TCC ATC TGA 
Genotyping 
hSOD1 Reverse CGC GAC TAA CAA TCA AAG TGA 
Internal positive ctrl Forward CTA GGC CAC AGA ATT GAA AGA TCT 
Internal positive ctrl Reverse GTA GGT GGA AAT TCT AGC ATC ATC C 
β-actin Forward (*) CTC TCA GCT GTG GTG GTG AA 
qRT-PCR 
β-actin Reverse (*) AGC CAT GTA CGT AGC CAT CC 
A1 Forward TCG GCT GGC TAC CAC CCC TTG 
A1 Reverse CCA GCA CCC AAG GTC ACA CCA AAG C 
A2A Forward ATT CCA CTC CGG TAC CGG TAC AAT GG 
A2A Reverse AGT TGT TCC AGC CCA GCA T 





















	   	  
Figure 12 | qRT-PCR calibration curve and quality control using SYBR Green method for β-actin mRNA 
quantification. (A) Amplification performed in Rotorgene 6000 for triplicated serial dilutions of diaphragm (1:5; 
1:25; 1:125, 1:625) regarding β-actin reference gene. Threshold was adjusted in both linear and logarithmic plots, 
to allow detection of product while it is still in the exponential phase, and finally set as showed for determination 
of Ct values. NTC and RT- controls show no amplification. (B) Calibration curve based on the Ct values extracted 
from previous analysis and plotted with an efficiency (E) of 1,01, slope (M) of -3,288 and a R2 of 0,99. (C) Melting 
curve for β-actin primers shows a single peak, representative of a single species of DNA molecule in the reaction. 























































Figure 13 | qRT-PCR calibration curve and quality control using SYBR Green method for A2AR mRNA 
quantification. (A) Amplification performed in Rotorgene 6000 for triplicated serial dilutions of diaphragm (1:5; 
1:25; 1:125, 1:625) regarding A2AR target gene. Threshold was adjusted in both linear and logarithmic plots, to 
allow detection of product while it is still in the exponential phase, and finally set as showed for determination of 
Ct values. NTC and RT- controls show no amplification. (B) Calibration curve based on the Ct values extracted 
from previous analysis and plotted with an efficiency (E) of 1,11, slope (M) of -3,089 and a R2 of 0,99. (C) 
Melting curve for A2AR primers shows a single peak, representative of a single species of DNA molecule in the 

















































Figure 14 | Immunoblot analysis of the expression levels of A2A adenosine receptor in control and hSOD1 
mutants (complete gel image). This image shows the diffuse pattern of A2AR protein bands in immunoblotting 
gels and consequently gives an idea of the optimization problems. (A) Immunoreactivity of A2AAR was performed 
in motor cortex, spinal cord and diaphragm homogenates of pre-symptomatic and (B) symptomatic animals. 
A2AAR runs at ~42 kDa in the western blot. As a loading control α-tubulin was used (~55 kDa). Graphs represents 
the mean quantification of A2A/tubulin intensity ratio of n=5. Error bars indicate the standard error and statistical 
comparison was performed by t-test. CTRL, wild-type control; SOD1, transgenic SOD1; ST, striatum; CX, cortex; 
SC, spinal cord; DP, diaphragm. 
